Form 4: BioAdaptives Director Receives Stock Compensation

Director Mark P. Frissora acquired 4,717 shares of Series D Convertible Preferred Stock as compensation for board services.

Summary

• Director Mark P. Frissora received 4,717 shares of Series D Convertible Preferred Stock on June 1, 2026.
• The issuance is part of a board compensation agreement dated February 3, 2025.
• Each share of Series D Preferred is convertible into 100 shares of common stock, totaling 471,700 potential common shares.
• Conversion is restricted until December 1, 2026, six months after the issuance date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.
• Preserves company cash by utilizing stock-based compensation for board services.

Negatives

• Potential for future dilution of common stock upon conversion of the preferred shares.

Risks

• Beneficial ownership limitation of 4.9% restricts the immediate conversion and liquidity of the holdings.
• Market volatility could impact the value of the underlying common stock upon the conversion date.

Future Outlook

The director holds the right to convert the preferred shares into common stock starting December 1, 2026, subject to a 4.9% ownership cap.

Management Comments

• The issuance represents compensation for board services pursuant to the agreement dated February 3, 2025.

Industry Context

StockSavvy.ai notes that small-cap companies frequently utilize preferred stock or equity grants to compensate board members to conserve cash flow, a common practice in the biotechnology and emerging growth sectors.

Comparison to Industry Standards

• Equity-based board compensation is standard practice for micro-cap companies to align incentives.
• The use of convertible preferred stock with a 4.9% ownership cap is a standard mechanism to manage regulatory reporting requirements and prevent excessive concentration of voting power.

Corporate Governance

Related Party Transactions

• Issuance of shares to a Director pursuant to a board service agreement.

Stakeholder Impact

• Shareholders may experience minor dilution upon the conversion of the preferred shares.

Next Steps

• Conversion of preferred shares to common stock on or after December 1, 2026.

Key Dates

Keywords

BioAdaptives, BDPT, Director Compensation, Form 4, Insider Trading, Equity Compensation